PIPERACILLIN/TAZOBACTAM - A NEW BETA-LACTAM BETA-LACTAMASE INHIBITOR COMBINATION - COMMENT

被引：0
|
作者：
WANG, F
SCHWENK, MH
机构：
来源：
ANNALS OF PHARMACOTHERAPY | 1995年 / 29卷 / 10期
关键词：
D O I：
10.1177/106002809502901026
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1051 / 1052
页数：2
相关论文
共 50 条
  • [21] BETA-LACTAMASE PRODUCTION AND RESISTANCE TO BETA-LACTAM ANTIBIOTICS IN NOCARDIA
    WALLACE, RJ
    VANCE, P
    WEISSFELD, A
    MARTIN, RR
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1978, 14 (05) : 704 - 709
  • [22] STRUCTURAL CHARACTERIZATION OF BETA-LACTAMASE INACTIVATED BY BETA-LACTAM SULFONES
    ELLERBY, LM
    FINK, AL
    HSIEH, M
    BIOPHYSICAL JOURNAL, 1987, 51 (02) : A312 - A312
  • [23] Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-Tazobactam
    Alosaimy, Sara
    Lagnf, Abdalhamid M.
    Hobbs, Athena L., V
    Mubarez, Musa
    Kufel, Wesley D.
    Morrisette, Taylor
    Polisetty, Radhika S.
    Li, David
    Veve, Michael P.
    Simon, Sam P.
    Truong, James
    Finch, Natalie
    Venugopalan, Veena
    Rico, Matthew
    Amaya, Lee
    Yost, Christine
    Cubillos, Ashley
    Chandler, Elisabeth
    Patch, Megan
    Smith, Ian Murphy Kelsey
    Biagi, Mark
    Wrin, Justin
    Moore, W. Justin
    Molina, Kyle C.
    Rebold, Nicholas
    Holger, Dana
    Coyne, Ashlan J. Kunz
    Jorgensen, Sarah
    Witucki, Paige
    Tran, Nikki N.
    Davis, Susan L.
    Sakoulas, George
    Rybak, Michael J.
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) : E1444 - E1455
  • [24] Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients
    François Barbier
    Sami Hraiech
    Solen Kernéis
    Nathanaël Veluppillai
    Olivier Pajot
    Julien Poissy
    Damien Roux
    Jean-Ralph Zahar
    Annals of Intensive Care, 13
  • [25] Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients
    Barbier, Francois
    Hraiech, Sami
    Kerneis, Solen
    Veluppillai, Nathanael
    Pajot, Olivier
    Poissy, Julien
    Roux, Damien
    Zahar, Jean-Ralph
    French Intens Care Soc
    ANNALS OF INTENSIVE CARE, 2023, 13 (01)
  • [26] BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS - DEVELOPMENT, ANTIBACTERIAL ACTIVITY AND CLINICAL-APPLICATIONS
    SUTHERLAND, R
    INFECTION, 1995, 23 (04) : 191 - 200
  • [27] Escape mutations circumvent a tradeoff between resistance to a beta-lactam and resistance to a beta-lactamase inhibitor
    Russ, Dor
    Glaser, Fabian
    Tamar, Einat Shaer
    Yelin, Idan
    Baym, Michael
    Kelsic, Eric D.
    Zampaloni, Claudia
    Haldimann, Andreas
    Kishony, Roy
    NATURE COMMUNICATIONS, 2020, 11 (01)
  • [28] Acute Kidney Injury in Patients Treated with IV Beta-Lactam/Beta-Lactamase Inhibitor Combinations
    Rutter, W. Cliff
    Burgess, David S.
    PHARMACOTHERAPY, 2017, 37 (05): : 593 - 598
  • [29] Escape mutations circumvent a tradeoff between resistance to a beta-lactam and resistance to a beta-lactamase inhibitor
    Dor Russ
    Fabian Glaser
    Einat Shaer Tamar
    Idan Yelin
    Michael Baym
    Eric D. Kelsic
    Claudia Zampaloni
    Andreas Haldimann
    Roy Kishony
    Nature Communications, 11
  • [30] COMBINATION BETA-LACTAM AND BETA-LACTAMASE-INHIBITOR THERAPY - PHARMACOKINETIC AND PHARMACODYNAMIC CONSIDERATIONS
    DUDLEY, MN
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1995, 52 (06) : S23 - S28
12345